Ayala Pharmaceuticals (NASDAQ:AYLA) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a sell rating to a hold rating in a research note released on Tuesday, Zacks.com reports.

According to Zacks, “Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala Pharmaceuticals Inc. is based in Rehovot, Israel. “

Several other research firms have also weighed in on AYLA. Noble Financial restated a buy rating and set a $29.00 price target on shares of Ayala Pharmaceuticals in a report on Friday, September 10th. LADENBURG THALM/SH SH began coverage on Ayala Pharmaceuticals in a research note on Tuesday, July 13th. They issued a buy rating and a $29.00 target price on the stock. Finally, Oppenheimer reduced their target price on Ayala Pharmaceuticals from $27.00 to $25.00 and set an outperform rating on the stock in a research note on Tuesday, August 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Ayala Pharmaceuticals currently has an average rating of Buy and an average price target of $25.75.

NASDAQ:AYLA opened at $14.08 on Tuesday. The stock’s fifty day moving average is $12.30 and its 200 day moving average is $11.42. Ayala Pharmaceuticals has a fifty-two week low of $7.74 and a fifty-two week high of $28.68. The firm has a market capitalization of $186.46 million, a PE ratio of -5.01 and a beta of -0.69.

Ayala Pharmaceuticals (NASDAQ:AYLA) last released its quarterly earnings results on Friday, August 13th. The company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.10). Ayala Pharmaceuticals had a negative net margin of 1,096.41% and a negative return on equity of 82.25%. As a group, analysts anticipate that Ayala Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Opaleye Management Inc. bought a new position in shares of Ayala Pharmaceuticals during the 1st quarter worth $1,184,000. Citadel Advisors LLC bought a new position in shares of Ayala Pharmaceuticals during the 2nd quarter worth $107,000. Morgan Stanley bought a new position in shares of Ayala Pharmaceuticals during the 1st quarter worth $46,000. Finally, Marshall Wace North America L.P. bought a new position in shares of Ayala Pharmaceuticals during the 2nd quarter worth $502,000. Institutional investors and hedge funds own 15.50% of the company’s stock.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

Further Reading: Liquidity

Get a free copy of the Zacks research report on Ayala Pharmaceuticals (AYLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.